Severity of acute pancreatitis in patients with inflammatory bowel disease in the era of biologics: A propensity‐score‐matched analysis using a nationwide database in Japan

Abstract

Background and Aim Acute pancreatitis (AP) is a rare extraintestinal manifestation of inflammatory bowel disease (IBD). Several studies from Western countries have reported that the severity of AP in patients with IBD is similar to that in the general population; however, its severity in patients from Eastern countries in the era of biologics remains unclear. This study aimed to investigate the severity of AP in patients with IBD and the effect of biologics on the severity of AP using a nationwide database. Methods We divided 1138 eligible AP admissions from the Diagnosis Procedure Combination database system into IBD and non‐IBD groups after propensity score matching, and compared the severity of AP. We divided the IBD group into ulcerative colitis (UC) and Crohn's disease (CD) subgroups and compared each with the non‐IBD group. Logistic regression analysis was conducted to identify the clinical factors affecting acute pancreatitis. Results IBD and UC groups had lower rate of severe AP compared to the non‐IBD group (13.7% vs 28.3%, P < 0.0001 and 11.0% vs 28.3%, P < 0.0001, respectively). There were no differences in the rates of severe AP between the CD and non‐IBD groups. Multivariate analysis showed that biologics did not affect the severity of AP. Conclusion The severity of AP in patients with IBD may be lower than that in the general population; biologics for IBD may not worsen its severity. Further prospective studies are required to clarify the severity of AP in patients with IBD.

A Clinical and Pathophysiological Overview of Intestinal and Systemic Diseases Associated with Pancreatic Disorders: Causality or Casualty?

“…Less frequent etiologies include metabolic causes, autoimmune pancreatic involvement, and duodenal obstruction or papillary inflammation [3]. When AP occurs in IBD patients, both pancreatic and intestinal disease outcomes appear unaffected by one another [7,8].…”

Clinical Utilization of Generic Drugs and Biosimilars for Ulcerative Colitis Treatment: Insights from a Nationwide Database Study in Japan

“…Previously, we conducted clinical research on lower gastrointestinal diseases using big data analytics on a national scale [8][9][10][11][12][13][14][15]. We herein contracted DeSC Healthcare, Inc. to use their dataset of national claim database.…”

Clinical practice and outcome of patients with elderly‐onset ulcerative colitis: Insights from a nationwide claims database study in Japan

“…On the contrary, a nationwide database, the so‐called big data, provides an adequate number of samples and enables the analysis of rare diseases and situations, such as those previously reported. 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 Therefore, this study aimed to clarify the clinical practice of EOUC and compare the differences in clinical course between EOUC and NEOUC using a nationwide claims database in Japan.…”